The enrolment period of this study was before the advent of angiotensin receptor/neprilysin inhibitor (ARNI) therapy, which has been shown to activate the parasympathetic nervous system significantly in patients with HF and reduced ejection fraction (Boehmer et al., 2024). The gene discussed is MME; the disease is hydrops fetalis.